Ketorolac a dosi più basse per il controllo del dolore analgesico in terapia intensiva: uno studio di fattibilità pilota (KETOROLAC-ICU)
Ketorolac a dosi più basse per il controllo del dolore analgesico in terapia intensiva: uno studio randomizzato, in cieco, in gruppo parallele, controllato con placebo per accertare l'effetto del ketorolac sui punteggi del dolore e l'uso di oppiacei per i malati di critica
Opiates are commonly used to control pain in critically ill patients in the ICU. However, increased rates of opiate use in hospital may lead to increased prescription-based opiate dependence after leaving the ICU. This may contribute to the ongoing opiate epidemic across the world. Other medications that can reduce pain, like non-steroidal anti-inflammatory drugs (NSAIDs), are being studied in critically ill patients. These drugs block the enzyme, cyclooxygenases (COX), which causes inflammation in the body. Blocking these enzymes can decrease pain, fever, and inflammation. Traditionally, NSAIDs are not commonly used in critically ill patients due to the perceived risk of gastrointestinal (GI) bleeding and acute kidney injury (AKI). However, many critically ill patients are already receiving medications and treatments to prevent GI bleeding and AKI and are closely monitored so these medications may be useful in reducing pain for these patients.
The purpose of this study is to see whether NSAIDs can be used safely in critically ill patients to reduce the dose of opiates required for pain control. This is a pilot study or a feasibility study, which is not expected to answer the question definitively. Its main purpose is to determine if NSAIDs could reduce the use of opiates in critically ill patients while in the ICU. The data collected in this study may be used in a larger study in the future.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Purpose: The purpose of this study is to determine the feasibility of conducting a future, adequately powered large-scale randomized trial, while evaluating the safety and efficacy of an intravenous NSAID (e.g., ketorolac) plus usual care as compared to placebo plus usual care in critically ill patients.
Hypothesis: The investigators hypothesize that this single-centre pilot study will demonstrate that NSAIDs administration is feasible and safe in ICU patients and may potentially reduce opiate use in ICU patients with pain.
Justification: Pain control in ICU is difficult to achieve given that opiates are the mainstay of analgesia in critically ill patients, but this is not without unintended side effects, especially unintended consequences of possible future drug dependence or addictions. Given that opiates and other adjunctive pain medications (e.g., acetaminophen) are being utilized at high proportional rates, and that NSAIDs are used at relatively low rates (due to the theoretical risk of increased AKI and GI bleeds), there is potential for practice change for increased NSAID use at lower doses to reduce pain and opiate use, while not increasing risks.
Objectives: The primary objective of this pilot trial is to assess the feasibility of a larger clinical trial utilizing NSAIDs in the ICU for patients with pain. The primary outcomes of the pilot feasibility trial are: recruitment and consent rates, proportion of eligible participants who are randomized vs. not randomized, retention and protocol adherence rates.
The secondary objectives are to assess safety of the proposed trial (e.g. gastrointestinal bleeding, acute kidney injury, death) and efficacy outcomes (e.g. participant pain scores, opiate and other analgesia usage).
Research Methods/Procedures: The investigators have designed KETOROLAC-ICU as a pilot randomized controlled trial (prospective, single centre, parallel-group, concealed, blinded) examining the use of low-dose ketorolac for critically ill patients.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 3
Contatti e Sedi
Contatto studio
- Nome: Vincent I Lau, MD MSc
- Numero di telefono: 780-492-9390
- Email: vince.lau@ualberta.ca
Luoghi di studio
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2B7
- Reclutamento
- University of Alberta Hospital
-
Contatto:
- Vincent I Lau, MD MSc
- Numero di telefono: 780-492-9390
- Email: vince.lau@ualberta.ca
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Age > 18 years
- Admission to intensive care unit (ICU)
- Participants with pain (Critical Care Pain Observation Tool [CPOT] > 1 and/or self-report pains score >1 on visual analogue scale [VAS] or numerical rating scale [NRS])
Exclusion Criteria:
- Serum Cr > 100 mmol/L for females, and >130 mmol/L for males
- Ongoing ACEi (angiotensin converting enzyme inhibitor)/ARB (angiotensin receptor blocker) use in ICU
- Known hyperkalemia > 5.5
- Pre-existing chronic kidney disease (CKD Stage > 3), defined by a serum Cr > 100 mmol/L for females, and >130 mmol/L for males (at the time of screening, based on pre-hospital stable outpatient baseline values)
- New acute kidney injury KDIGO Stage > 2 (increased more than > 2-to-3 times in serum creatinine above baseline AND/OR <0.5mL/kg/hour urine output for >12 hours)
- Pre-existing gastrointestinal bleeding (within 12 weeks of hospital admission, requiring hospitalization or medical evaluation), new peptic ulcer disease, esophagitis, esophageal varices within the last 3 months
- Active gastric / duodenal / peptic ulcer, active GI bleeding
- Prior contraindications/allergies to NSAIDS or stress ulcer prophylaxis, specifically if a participant has had an anaphylactic reaction (asthma or urticaria) or non-anaphylactic asthma reaction to NSAIDs or any stress ulcer prophylaxis, e.g. proton pump inhibitor, histamine-2-blockers, etc. (e.g. proton pump inhibitor, histamine-2-blockers, etc.)
- Complete or partial syndrome of ASA-intolerance (e.g. rhinosinusitis, urticaria/angioedema, nasal polyps, asthma)
- Participants who are not receiving stress ulcer prophylaxis (e.g. proton pump inhibitor, histamine-2-blockers, etc.) while in ICU
- Any active bleeding (requiring any blood products or adjunctive coagulation agents, any output of blood >100 mL/hr, e.g. chest tube drainage, abdominal cavity drain, etc.)
- Currently receiving NSAID(s) for another indication
- Inflammatory bowel disease (e.g. participants with prior diagnosis of Crohn's disease or ulcerative colitis)
- Receiving probenecid, oxpentifylline or pentoxifylline
- Active ischemic heart disease (acute myocardial infarction, acute coronary syndrome during current hospital admission)
- Moderate-severe uncontrolled heart failure (New York Heart Association: Class II-IV)
- Moderate to severe liver impairment or active liver disease (Operational definition: participants with prior history of Child-Pugh class B (moderate) or C (severe) liver cirrhosis, OR Model for End-Stage Liver Disease-Sodium (MELD-Na) score >25, OR active acute liver failure: severe acute liver injury with encephalopathy and impaired synthetic function International Normalized Ratio (INR) >1.5 with or without pre-existing liver disease)
- Active cerebrovascular bleeding or stroke (cerebrovascular accident, transient ischemic attacks and/or amaurosis fugax, e.g. participants with active stroke symptoms within current hospital admission)
- Cerebrovascular bleeding or other bleeding disorders
- Coagulation disorders, post-operative patients with high haemorrhagic risk or incomplete haemostasis in patients with suspected or confirmed cerebrovascular bleeding
- Neuraxial (epidural or intrathecal) administration of ketorolac tromethamine injection due to its alcohol content
- Rhabdomyolysis (creatinine kinase >5000 U/L)
- Recent transplant (during same hospital admission, e.g., heart, lung, kidney, liver, etc.)
- Known allergy to ketorolac or other NSAIDs
- Participants expected to stay in ICU < 48 hours
- In the opinion of the attending physician, expected death or withdrawal of life-sustaining treatments within 48 hours
- Participant is known to be pregnant and/or breastfeeding
- Most responsible physician, participant, or substitute decision maker declines study participation (and reason)
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Ketorolac
Ketorolac administration + standard of care. Participants will not be allowed to have co-administered alternative NSAIDs during the duration of their exposure on the study drug. After each administered dose, overall analgesic requirements should be assessed by the treating team (as per local institutional guidelines and practices), with attempts to wean analgesic infusions or use reduced doses of analgesic medications (especially if objective pain score measures are zero, e.g. CPOT or NRS/VAS). |
Ketorolac 15 mg IV q6h for a maximum of 3 days total or discharge from ICU (whichever comes first). The ketorolac will be diluted in a 0.9% normal saline 10 mL syringe. |
|
Comparatore placebo: Placebo
Placebo administration + standard of care. Participants will not be allowed to have co-administered alternative NSAIDs during the duration of their exposure on the study drug. After each administered dose, overall analgesic requirements should be assessed by the treating team (as per local institutional guidelines and practices), with attempts to wean analgesic infusions or use reduced doses of analgesic medications (especially if objective pain score measures are zero, e.g. CPOT or NRS/VAS). |
Matching placebo IV q6h for a maximum of 3 days total or discharge from ICU (whichever comes first). The matching placebo will be diluted in a 0.9% normal saline 10 mL syringe. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Feasibility - Recruitment and Retention
Lasso di tempo: Days 1-7, 90
|
Recruitment rate at pilot site (participants/month), consent rates of eligible participants, proportion of eligible participants not randomized, and participant retention rates. |
Days 1-7, 90
|
|
Feasibility - Protocol Adherence
Lasso di tempo: Days 1-7, 90
|
Rates of protocol adherence and reasons for protocol non-adherence. |
Days 1-7, 90
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Opioid Use
Lasso di tempo: Baseline; Days 1-7, 14, 21, 28, 90
|
The administration of opioid medications (converted into oral morphine equivalents) |
Baseline; Days 1-7, 14, 21, 28, 90
|
|
Pain Scores - Critical Care Pain Observation Tool (CPOT)
Lasso di tempo: Baseline; Days 1-7, 14, 21, 28
|
The critical care pain observation tool (CPOT) is used by healthcare workers to measure four indicators of pain: facial expression, body movements, muscle tension, and compliance with the ventilator (or vocalization for extubated participants). Each of the four indicators are ranked from 0 to 2, with higher numbers describing more pain behaviors. |
Baseline; Days 1-7, 14, 21, 28
|
|
Pain Scores - Visual Analog Scale (VAS)
Lasso di tempo: Baseline; Days 1-7, 14, 21, 28
|
The visual analog scale (VAS) is a self-reported measure of a participant's level of pain. This tool consists of a single, 10cm long line, with one end titled "No pain" and the other end titled "Pain as bad as it could possibly be." The participant then draws a mark on the line that corresponds to their level of pain. This mark is later quantified in distance from the "no pain" side of the line. |
Baseline; Days 1-7, 14, 21, 28
|
|
Pain Scores - Numerical Pain Rating Scale (NRS)
Lasso di tempo: Baseline; Days 1-7, 14, 21, 28
|
The numerical pain rating scale (NRS) is a self-reported measure of a participant's level of pain. Participants are asked to rank their pain on a scale of 0 to 10, with 0 representing no pain, and 10 representing the worst possible pain. |
Baseline; Days 1-7, 14, 21, 28
|
|
Safety - Acute Kidney Injury
Lasso di tempo: Days 1-7, 28
|
KDIGO Stage ≥ 2 (increased serum creatinine > 2-3 times above baseline AND/OR <0.5mL/kg/hour urine output for >12 hours) AND/OR need for renal replacement therapy |
Days 1-7, 28
|
|
Safety - Gastrointestinal (GI) Bleeding
Lasso di tempo: Days 1-7, 28
|
Clinically significant GI bleeding (visual and physiological evidence of overt GI bleeding) |
Days 1-7, 28
|
|
Safety - Other
Lasso di tempo: Days 1-28
|
Occurrence of any adverse and/or serious adverse events |
Days 1-28
|
|
All-Cause Mortality
Lasso di tempo: Days 28, 90
|
All-cause mortality in ICU, in hospital, or post-discharge. |
Days 28, 90
|
|
Health-Related Quality of Life (EQ-5D-5L)
Lasso di tempo: Day 90
|
EuroQol's Health-Related Quality of Life questionnaire (EQ-5D-5L) is a self-reported measure of a participant's current health status and quality of life. This questionnaire consists of 5 questions, each representing a different dimension of health-related quality of life: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each question has 5 possible responses, ranging from "no problem" (score of 1) to "unable/extreme problems" (score of 5). |
Day 90
|
|
Clinical Frailty Scale (CFS)
Lasso di tempo: Baseline; Day 90
|
The Clinical Frailty Scale (CFS) is a tool to describe a participant's frailty and level of functioning. This scale ranges from "Very Fit" (score of 1) to "Terminally Ill" (score of 9). |
Baseline; Day 90
|
|
Cognitive Measures
Lasso di tempo: Days 1-28
|
Delirium incidence (ICDSC scores ≥ 4), duration of decreased level of consciousness (LOC) due to moderate-severe sedation (RASS scores ≤ -3), duration of decreased LOC requiring intubation or ongoing mechanical ventilation (GCS < 8) |
Days 1-28
|
|
Organ Support
Lasso di tempo: Days 1-7, 14, 21, 28, 90
|
Use and duration of invasive mechanical ventilation (including rates of reintubation), non-invasive ventilation, renal replacement therapy, and vasopressors |
Days 1-7, 14, 21, 28, 90
|
|
Length of Admission
Lasso di tempo: Day 90
|
ICU length of stay, hospital length of stay, readmission episodes |
Day 90
|
|
Procedures
Lasso di tempo: Days 1-7, 28
|
Need for endoscopy (EGD or colonoscopy), angiography, and/or exploratory laparotomy |
Days 1-7, 28
|
|
Other Analgesia
Lasso di tempo: Days 1-7, 14, 21, 28, 90
|
Administration of non-opioid analgesic medications |
Days 1-7, 14, 21, 28, 90
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Vincent I Lau, MD MSc, University of Alberta
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- Pro00126948
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .